Table 1.
Baseline characteristics and clinical history
| 74 Gy in 37 fractions (n=676) | 60 Gy in 20 fractions (n=686) | 57 Gy in 19 fractions (n=692) | ||
|---|---|---|---|---|
| Age (years) | 69 (65–73) | 69 (64–73) | 68 (64–73) | |
| T stage | ||||
| T1a/1b/1c/1x | 224 (33%) | 273 (40%) | 252 (36%) | |
| T2a/b/c/x | 393 (58%) | 355 (52%) | 368 (53%) | |
| T3a/x | 59 (9%) | 57 (8%) | 71 (10%) | |
| Unknown | 0 (0%) | 1 (<1%) | 1 (<1%) | |
| Gleason score | ||||
| ≤6 | 248 (37%) | 252 (37%) | 233 (34%) | |
| 7 | 406 (60%) | 413 (60%) | 432 (62%) | |
| 8 | 22 (3%) | 21 (3%) | 27 (4%) | |
| Prostate-specific antigen (ng/mL) | ||||
| Median (IQR) | 10·4 (7·3–14·6) | 11·0 (7·8–15·5) | 10·4 (7·2–14·5) | |
| Mean (SD) | 11·3 (5·3) | 11·9 (5·8) | 11·3 (5·4) | |
| 0·00–4·99 | 44 (7%) | 51 (7%) | 46 (7%) | |
| 5·00–9·99 | 267 (39%) | 249 (36%) | 274 (40%) | |
| 10·00–19·90 | 319 (47%) | 327 (48%) | 321 (46%) | |
| 20·00–40·00 | 46 (7%) | 59 (9%) | 49 (7%) | |
| Unknown | 0 (0%) | 0 (0%) | 2 (<1%) | |
| NCCN risk group | ||||
| Low | 104 (15%) | 113 (16%) | 109 (16%) | |
| Intermediate | 496 (73%) | 498 (73%) | 496 (72%) | |
| High | 76 (11%) | 75 (11%) | 87 (13%) | |
| Diabetes | ||||
| Yes | 74 (11%) | 65 (9%) | 77 (11%) | |
| No | 599 (89%) | 619 (90%) | 606 (88%) | |
| Unknown | 3 (<1%) | 2 (<1%) | 9 (1%) | |
| Hypertension | ||||
| Yes | 248 (37%) | 281 (41%) | 273 (39%) | |
| No | 423 (63%) | 403 (59%) | 414 (60%) | |
| Unknown | 5 (<1%) | 2 (<1%) | 5 (<1%) | |
| Inflammatory bowel or diverticular disease | ||||
| Yes | 25 (4%) | 21 (3%) | 27 (4%) | |
| No | 646 (96%) | 663 (97%) | 659 (95%) | |
| Unknown | 5 (<1%) | 2 (<1%) | 6 (1%) | |
| Previous pelvic surgery | ||||
| Yes | 55 (8%) | 51 (7%) | 53 (8%) | |
| No | 616 (91%) | 633 (92%) | 632 (91%) | |
| Unknown | 5 (<1%) | 2 (<1%) | 7 (1%) | |
| Symptomatic haemorrhoids in past 12 months | ||||
| Yes | 39 (6%) | 50 (7%) | 52 (8%) | |
| No | 620 (92%) | 617 (90%) | 623 (90%) | |
| Unknown | 17 (3%) | 19 (3%) | 17 (2%) | |
| Previous transurethral resection of the prostate | ||||
| Yes | 55 (8%) | 61 (9%) | 62 (9%) | |
| No | 606 (90%) | 615 (90%) | 617 (89%) | |
| Unknown | 15 (2%) | 10 (1%) | 13 (2%) | |
| Hormone treatment duration (days)* | 140 (113–169) | 132 (102–165) | 127 (102–157) | |
| Time from androgen suppression to start of radiotherapy (days) | 116 (103–138) | 118 (103–138) | 115 (103–139) | |
| Time from radiotherapy start to end of androgen suppression (days)† | 16 (−3 to 42) | 6 (−6 to 24) | 6 (−7 to 23) | |
Data are n (%) or median (IQR) unless otherwise stated. NCCN=National Comprehensive Cancer Network.
*
Hormone treatment duration was the total duration, including before study entry.
†
Negative values are from patients who stopped androgen suppression before starting radiotherapy.